GlassScriptPhysician profile
Sunil T Ramaprasad
NPI 1679563100
$82,717.22
in general payments reported to CMS, 2019-2025
46 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $11K · 2021: $17K · 2022: $11K · 2023: $1,920 · 2024: $2,106 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,539 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,538.76 |
| Education | $143.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61,767.98 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $8,024.05 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3,137.98 | 2019-2025 | Lifevest |
| Medtronic, INC. | $988.63 | 2021-2025 | Ffrangio, Selectsecure, Micra |
| Novo Nordisk INC | $943.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $887.82 | 2019-2023 | Farxiga |
| Amgen INC. | $777.91 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $718.68 | 2019-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $606.39 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ultreon |
| Medtronic Vascular, INC. | $458.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $422.44 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $412.89 | 2019-2024 | |
| Boston Scientific Corporation | $385.26 | 2019-2025 | General - Catheter, General - Therapies, Bodyguardian |
| Amarin Pharma, INC. | $362.51 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $237.15 | 2019-2025 | Camzyos, Eliquis |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Ramaprasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.